Corporate Banner
Satellite Banner
Technology Networks Header
Monday, January 26, 2015
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
Novogen Announces Important Discovery in Regenerative Medicine Program
A key proof-of-concept step to develop drugs capable of stimulating the function of brain tissue stem cells.
Stanford Chemists Take Step Toward Solving Mystery of How Enzymes Work
Steven Boxer and his students have found that the electrostatic field within an enzyme accounts for the lion's share of its success.
New Class of Synthetic Molecules Mimics Antibodies
A Yale University lab has crafted the first synthetic molecules that have both the targeting and response functions of antibodies.
The Hunt for Botanicals
Herbal medicine can be a double-edged sword and should be more rigorously investigated for both its beneficial and harmful effects, say researchers writing in a special supplement of Science.
Novel Agent Decreases Neuropathic Pain in Patients with Type 2 Diabetes
Promising profile of disease modification and pain reduction leads to proof of concept trials.
Barrier-Breaking Drug May Lead to Spinal Cord Injury Treatments
NIH-funded scientists take first step towards developing promising new drug.
Two Drugs are No More Effective Than One to Treat Common Kidney Disease
NIH study finds limited kidney benefit from more rigorous blood pressure treatment.
Antibiotic Resistance Threatens Future of Modern Medicine
Overuse and misuse of antibiotics, one of the key contributors to antimicrobial resistance (AMR).
Computer Model Sets New Precedent in Drug Discovery
New computational model can precisely simulate, predict therapeutic protein behaviors to help zero in on ideal drug design candidates.
New Drug for Common Liver Disease Improves Liver Health
An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the NIH.
Scroll Up
Scroll Down
Return
Fragment Based Drug Discovery of Novel MK2 Inhibitors
Thomas Hesterkamp, VP Fragment Based Drug Discovery, Evotec AG, speaking at MedChem Europe 2009
Date Posted: Thursday, November 19, 2009
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Evotec and Padlock Therapeutics Extend Collaboration
Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration.
Friday, January 09, 2015
Evotec And The Jain Foundation Expand Collaboration
The collaboration marks the start of multiple drug screening programmes.
Monday, September 15, 2014
Evotec, Medicines for Malaria Announce Compound Management Collaboration
The collaboration will support MMV’s Malaria and Pathogen Box initiatives.
Tuesday, August 19, 2014
Evotec, Fraunhofer in Drug Discovery Collaboration
The exclusive, strategic collaboration will combine the relevant platforms of both organisations, focusing on several disease areas.
Tuesday, July 08, 2014
Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim
The milestone relates to the transition of an oncology molecule into pre-clinical development.
Tuesday, December 10, 2013
Evotec and Dow AgroSciences Collaborate on Cellular Target Profiling
Collaboration has objective of leveraging Evotec’s advanced chemical proteomics services to support compounds in development at Dow AgroSciences.
Tuesday, July 09, 2013
Evotec Extends Ongoing Collaboration with CHDI Foundation
Collaboration aims to accelerate development of drugs that slow the progression of Huntington's disease.
Monday, November 05, 2012
Evotec and Bayer Enter into Multi-target Alliance to Fight Endometriosis
Companies have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis.
Monday, October 01, 2012
Evotec and IR Pharma Establish Drug Discovery Alliance
Companies have entered into an exclusive strategic alliance to provide integrated drug discovery solutions to Pharmaceutical and Biotech companies in the field of Respiratory Diseases.
Thursday, February 16, 2012
Evotec and Merck KGaA to Collaborate on Neurological Disease Target
Evotec to apply integrated drug discovery expertise and technologies to identify interesting small molecules for the selected target.
Wednesday, November 24, 2010
Evotec and APEIRON Biologics build Pain Alliance
The collaboration will initially identify small molecule modulators of DREAM - Downstream Regulatory Element Antagonistic Modulator.
Monday, November 01, 2010
Evotec Licenses Phase II Insomnia Candidate to Jingxin Pharma for Development in China
Jingxin Pharma will initiate clinical trials with EVT 201 in China in 2011.
Monday, November 01, 2010
Evotec Completes Acquisition of DeveloGen
The transaction adds two complementary alliances - one with Boehringer Ingelheim and one with Andromeda to Evotec's portfolio of core assets.
Friday, September 03, 2010
Evotec Earns Milestone in Oncology Programme as Part of its Research Alliance with Boehringer Ingelheim
The milestone was achieved for the selection of a candidate compound for pre-development studies in an oncology programme.
Thursday, June 17, 2010
Evotec Brings Project in Neuropathic Pain into Clinical Development in its Alliance with Boehringer Ingelheim
Evotec receives EUR 2.0M milestone payment with initiation of the Phase I clinical studies for the compound.
Thursday, May 20, 2010
 
Skyscraper Banner
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn